Investment in Affiliated Companies, Net (Details Narrative) - USD ($) $ in Thousands |
12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 02, 2020 |
Aug. 31, 2020 |
Jul. 31, 2020 |
Jul. 16, 2020 |
Jul. 12, 2020 |
Jun. 14, 2020 |
Feb. 27, 2019 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Jul. 27, 2020 |
Jun. 13, 2020 |
|
| Stock issued during the period, shares | 2,164,502 | ||||||||||
| Ownership percentage, description | Affiliated company is company held to the extent of 20% or more (which are not subsidiary), or company less than 20% held, which the Company can exercise significant influence over operating and financial policy of the affiliate. | ||||||||||
| Research and development expenses | $ 9,863 | $ 756 | |||||||||
| Investment in affiliated company | 745 | ||||||||||
| Share in losses of affiliated company | $ (1,200) | (2,966) | |||||||||
| Ordinary Shares [Member] | |||||||||||
| Stock issued during the period, shares | 6,000,000 | ||||||||||
| NLC Pharma Ltd [Member] | |||||||||||
| Ownership percentage | 15.00% | 80.00% | |||||||||
| Stock issued during the period, shares | 2,688,172 | ||||||||||
| Proceeds from gross sales | $ 20,000 | ||||||||||
| Cash | 1,650 | ||||||||||
| Value of granted shares | $ 1,500 | ||||||||||
| Zegal and Ross Capital LLC [Member] | |||||||||||
| Ownership percentage | 10.00% | ||||||||||
| Bio Imagery [Member] | |||||||||||
| Ownership percentage | 67.00% | ||||||||||
| Investment in affiliated company | $ 618 | ||||||||||
| Bio Imagery [Member] | Restricted Ordinary Shares [Member] | |||||||||||
| Stock issued during the period, shares | 6,000,000 | ||||||||||
| Care GB [Member] | |||||||||||
| Ownership percentage | 33.00% | ||||||||||
| Percentage of shares will grant | 15.00% | ||||||||||
| Joint Venture Agreement [Member] | |||||||||||
| Residual amount | $ 1,345 | ||||||||||
| Fair value of equity consideration | 2,518 | ||||||||||
| Fair value of option transaction | $ 1,173 | ||||||||||
| Expenses related to investment | 1,345 | ||||||||||
| Expenses related to option transaction | 1,173 | ||||||||||
| Interest free loan | $ 448 | ||||||||||
| Joint Venture Agreement [Member] | Amarantus Bioscience Holdings, Inc. [Member] | |||||||||||
| Ownership percentage | 49.90% | 19.99% | 19.90% | ||||||||
| Stock issued during the period, shares | 67,599,796 | 17,986,999 | |||||||||
| Remaining ownership percentage | 80.10% | ||||||||||
| Option transaction percentage | 30.01% | 30.01% | |||||||||
| Ownership percentage, description | In exchange for the remaining 80.1% equity interest of Breakthrough, the Company will issue 49.9% of its ordinary shares (which including 19.9% ordinary shares that were already issued) based on the capitalization table of the Company on regular basis as of December 31, 2019. | On February 27, 2019 (the "Effective Date"), following execution of the Convertible bridge loan transactions (see also Note 11), the Company signed a Definitive Joint Venture Agreement (the "Joint Venture Agreement") and closed the Joint Venture Transaction, pursuant to which the Company issued 19.99% of its outstanding ordinary shares to Amarantus Bioscience Holdings, Inc. ("Amarantus"), a biotechnology holding company, in exchange for 19.99% of Breakthrough Diagnostics, Inc., a wholly-owned subsidiary of Amarantus ("Breakthrough"), and Amarantus assigned to Breakthrough exclusive license to develop and commercialize the LymPro Test®, an immune-based neurodiagnostic blood test for the detection of Alzheimer's disease (the "License"). The transaction was consummated as of February 27, 2019 (the "Closing Date") in which the Company issued to Amarantus 17,986,999 ordinary shares (the "Equity Consideration"). In addition, Amarantus granted the Company an exclusive option, in effect for 60-days from the Closing Date (the "Expiration Date"), to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of the Company's outstanding shares (the "Option Transaction"). Upon exercise of the Option Transaction, the Company would own 100% of Breakthrough and Amarantus would own 49.99% of the Company. The Company was required to notify Amarantus in writing of its intention to exercise the Option, and the closing of the Option transaction shall take place within fourteen days of Amarantus' receipt of such notice. | |||||||||
| Fair value of equity consideration | 6,084 | ||||||||||
| Fair value of option transaction | $ 1,623 | ||||||||||
| Royalty fee percentage | 10.00% | ||||||||||
| Payment of cash consideration | $ 450 | ||||||||||
| Research and development expenses | $ 8,157 | ||||||||||
| Joint Venture Agreement [Member] | Subsediary and Amarantus Bioscience Holdings, Inc. [Member] | |||||||||||
| Remaining ownership percentage | 49.99% | ||||||||||
| Joint Venture Agreement [Member] | Breakthrough [Member] | |||||||||||
| Ownership percentage | 100.00% | ||||||||||
| Assignment of License Agreement [Member] | Breakthrough Diagnostics, Inc. [Member] | |||||||||||
| Ownership percentage | 19.99% | 80.01% | |||||||||
| Remaining ownership percentage | 80.01% | ||||||||||
| License Agreement [Member] | |||||||||||
| Royalty fee percentage | 80.00% | ||||||||||
| Distribution Agreement [Member] | |||||||||||
| Research and development expenses | $ 1,550 | ||||||||||
| Antigen COVID Test Killer [Member] | |||||||||||
| Ownership percentage | 10.00% | ||||||||||
| Ownership percentage, description | Upon achieving milestone proof of concept that includes (i) conducting successful test within a la environment and (ii) initiation of a multicenter clinical trial (the "Performance Milestone"), the Company shall acquire during a period of one year after achieving the Performance Milestone an additional 5% of CATK from NLC for a sum of $250 to be paid for in shares of the Company based on market value of the shares at the closing price of a day prior to share issuance. The Performance Milestone has been achieved at July 12, 2020, and 2,688,172 Company's shares were issued to NLC. | ||||||||||
| Sale of stock description | In addition, if CATK sales will be in excess of $32,500 and the Company will complete an uplisting to Nasdaq within one year of signing the amendment, then the Company will fully acquire CATK in a share exchange transaction based on value of $65,000 and NLC shall transfer the IP regarding Viral Testing to the Joint Venture and NLC will have the right to appoint one member of the Company's Board of Directors. | ||||||||||
| Investment in affiliated company | $ 2,718 | ||||||||||
| Share in losses of affiliated company | 105 | ||||||||||
| Antigen COVID Test Killer [Member] | In Process Research and Development [Member] | |||||||||||
| Investment in affiliated company | $ 127 | ||||||||||
| Distribution Rights [Member] | |||||||||||
| Ownership percentage | 22.00% | 10.00% | |||||||||
| Royalty fee percentage | 8.00% | ||||||||||